Gedar Totuk O M, Kabadayi K, Colakoglu A, Ekizoglu N, Aykan U
Department of Ophthalmology, Bahcesehir University Faculty of Medicine, Yenisahra Mah. Batman Sok. No: 66-68 Sahrayicedit, Kadikoy, Istanbul, Turkey.
Bahcesehir University Faculty of Medicine, Istanbul, Turkey.
BMC Ophthalmol. 2018 Aug 31;18(1):226. doi: 10.1186/s12886-018-0907-y.
To describe a new technique and present its long-term outcome for prevention of Ahmed glaucoma valve (AGV) tube exposure in patients with refractory glaucoma.
Twenty-seven eyes of 24 patients (mean age, 50 years; age range, 16-78 years; 8 females, 16 males) with refractory glaucoma who had the AGV implant were retrospectively reviewed. For AGV implantation, a long scleral flap combined with Tenon advancement and duplication was used. In this technique, a long scleral flap is created to completely cover the extraocular part of valve's tube, and the flap surface is covered with duplicated Tenon's tissue. The average follow-up after AGV implantation was 21.7 months (range, 12-36 months).
The mean intraocular pressure before the operation, which was 44.1 mmHg (range, 26-62 mmHg), decreased to 14.2 mmHg (range, 8-20 mmHg) at the last follow-up visit, showing 67% reduction with AGV implantation. The mean number of antiglaucomatous medications was 4.1 before the AGV implantation and decreased to 0.9 after the operation, showing 88% reduction. In 14 eyes (51.9%), there was no change in the best corrected visual acuity (BCVA), and in 11 eyes (40.7%), the BCVA increased by 2 lines on the Snellen chart postoperatively. No patient developed postoperative hypotony, flat anterior chamber, diplopia, strabismus, erosion or exposure of the tube, or tube/plate migration.
The long scleral flap augmented with Tenon advancement and duplication is an effective and safe surgical technique for the implantation of AGV and preventing tube exposure in cases of refractory glaucoma.
描述一种新技术并展示其预防难治性青光眼患者 Ahmed 青光眼引流阀(AGV)引流管暴露的长期效果。
回顾性分析 24 例(平均年龄 50 岁;年龄范围 16 - 78 岁;女性 8 例,男性 16 例)难治性青光眼患者植入 AGV 的 27 只眼。对于 AGV 植入,采用长巩膜瓣联合眼球筋膜推进和重叠术。在该技术中,制作一个长巩膜瓣以完全覆盖引流阀引流管的眼外部分,瓣表面覆盖重叠的眼球筋膜组织。AGV 植入后的平均随访时间为 21.7 个月(范围 12 - 36 个月)。
术前平均眼压为 44.1 mmHg(范围 26 - 62 mmHg),在最后一次随访时降至 14.2 mmHg(范围 8 - 20 mmHg),AGV 植入后眼压降低了 67%。AGV 植入前抗青光眼药物的平均数量为 4.1 种,术后降至 0.9 种,减少了 88%。14 只眼(51.9%)最佳矫正视力(BCVA)无变化,11 只眼(40.7%)术后 BCVA 在 Snellen 视力表上提高了 2 行。没有患者出现术后低眼压、无前房、复视、斜视、引流管侵蚀或暴露,或引流管/引流盘移位。
长巩膜瓣联合眼球筋膜推进和重叠术是一种有效且安全的手术技术,用于 AGV 植入及预防难治性青光眼病例中的引流管暴露。